https://orcid.org/0000-0002-8400-2198
Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Aide Negri, Marina Marozzi, Daniela Trisciuoglio, Dante Rotili, Antonello Mai & Federica Rizzi. (2023) Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells. Journal of Enzyme Inhibition and Medicinal Chemistry 38:1.
Read now
Read now
Articles from other publishers (24)
Jianan Ju, Hao Zhang, Shanshan Guan, Chang Liu, Juan Du, Xiaoli Shen & Song Wang. (2023) Insight into the Inhibitory Mechanism of Embryonic Ectoderm Development Subunit by Triazolopyrimidine Derivatives as Inhibitors through Molecular Dynamics Simulation. Molecules 28:24, pages 7997.
Crossref
Crossref
Derek VanDyke, Linda Xu, Paul R. Sargunas, Ryan N. Gilbreth, Manuel Baca, Changshou Gao, James Hunt & Jamie B. Spangler. (2023) Redirecting the specificity of tripartite motif containing-21 scaffolds using a novel discovery and design approach. Journal of Biological Chemistry 299:12, pages 105381.
Crossref
Crossref
James K. Fields, Chad W. Hicks & Cynthia Wolberger. (2023) Diverse modes of regulating methyltransferase activity by histone ubiquitination. Current Opinion in Structural Biology 82, pages 102649.
Crossref
Crossref
Sarah Naiyer, Lalita Dwivedi, Nishant Singh, Swastik Phulera, Vijay Mohan & Mohammad Kamran. (2023) Role of Transcription Factor BEND3 and Its Potential Effect on Cancer Progression. Cancers 15:14, pages 3685.
Crossref
Crossref
Yang Long, Yuqin Wang, Mengxia Qu, Di Zhang, Xiaotian Zhang & Junjie Zhang. (2023) Combined inhibition of EZH2 and the autotaxin-LPA-LPA2 axis exerts synergistic antitumor effects on colon cancer cells. Cancer Letters 566, pages 216226.
Crossref
Crossref
Yajie Shi, Qiuyue Zhang, Maoying Zhang, Yongsong Chen, Jianwen Sun, Lu Chen, Sen Liu, Zhongbo Liu, Jingyu Yang, Chunfu Wu, Zhonghui Zheng, Lihui Wang & Guoliang Chen. (2023) Discovery of Dual Lysine Methyltransferase G9a and EZH2 Inhibitors with In Vivo Efficacy against Malignant Rhabdoid Tumor. Journal of Medicinal Chemistry 66:8, pages 5685-5702.
Crossref
Crossref
Yongxia Zhu, Lidan Zhang, Xuejiao Song, Qiangsheng Zhang, Ting Wang, Hongtao Xiao & Luoting Yu. (2023) Pharmacological inhibition of EZH2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo. Biochemical Pharmacology 210, pages 115493.
Crossref
Crossref
Qiangsheng Zhang, Xinyi Chen, Jiaying Cao, Wan Yang, Guoquan Wan, Qiang Feng, Shuyan Zhou, Hongling Yang, Ningyu Wang, Zhihao Liu, Hongtao Xiao, Yongxia Zhu & Luoting Yu. (2023) Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer. Journal of Medicinal Chemistry 66:3, pages 1725-1741.
Crossref
Crossref
Tianfu Yu, Fengqi Zhou, Wei Tian, Ran Xu, Binbin Wang, Ailiang Zeng, Zhijun Zhou, Min Li, Yingyi Wang & Junxia Zhang. (2022) EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma. Oncogene 42:6, pages 461-470.
Crossref
Crossref
Wuhan Yu, Ning Liu, Xiaogang Song, Lang Chen, Mancai Wang, Guohui Xiao, Tengfei Li, Zheyuan Wang & Youcheng Zhang. (2023) EZH2: An Accomplice of Gastric Cancer. Cancers 15:2, pages 425.
Crossref
Crossref
Maria E. Gonzalez, Giuseppina Daniela Naimo, Talha Anwar, Alessandro Paolì, Shilpa R. Tekula, Suny Kim, Natasha Medhora, Shoshana A. Leflein, Jacob Itkin, Raymond Trievel, Kelley M. Kidwell, Yu-Chih Chen, Loredana Mauro, Euisik Yoon, Sebastiano Andò & Celina G. Kleer. (2022) EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression. iScience 25:8, pages 104827.
Crossref
Crossref
Haixiang Pei, Weikai Guo, Yangrui Peng, Hai Xiong & Yihua Chen. (2022) Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective. Medicinal Research Reviews 42:4, pages 1607-1660.
Crossref
Crossref
Juan Xia, Jingyi Li, Lei Tian, Xiaodong Ren, Chang Liu & Chengyuan Liang. (2022) Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure–Activity Relationships Insights and Evolution Prospects. Journal of Medicinal Chemistry 65:10, pages 7016-7043.
Crossref
Crossref
Thomas Webb, Conner Craigon & Alessio Ciulli. (2022) Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective. Bioorganic & Medicinal Chemistry Letters 63, pages 128653.
Crossref
Crossref
Raffaella Catalano, Annalisa Maruca, Roberta Rocca, Pierfrancesco Tassone, Giulia Panzarella, Giosuè Costa, Francesco Ortuso & Stefano Alcaro. (2022) Identification of SET/EED dual binders as innovative PRC2 inhibitors. Future Medicinal Chemistry.
Crossref
Crossref
Yuan Zhao, Yuan-Yuan Guan, Fang Zhao, Tong Yu, Shao-Jie Zhang, Yi-Zhe Zhang, Ying-Chao Duan & Xiao-Li Zhou. (2022) Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs. European Journal of Medicinal Chemistry 231, pages 114144.
Crossref
Crossref
Mallika Vijayanathan, María Guadalupe Trejo-Arellano & Iva Mozgová. (2022) Polycomb Repressive Complex 2 in Eukaryotes—An Evolutionary Perspective. Epigenomes 6:1, pages 3.
Crossref
Crossref
Liyuan Wang, Chan Chen, Zemin Song, Honghong Wang, Minghui Ye, Donghai Wang, Wenqian Kang, Hudan Liu & Guoliang Qing. (2022) EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation. Nature Communications 13:1.
Crossref
Crossref
Sharan K. Bagal, Clare Gregson, Daniel H. O’ Donovan, Kurt G. Pike, Andrew Bloecher, Peter Barton, Alexandra Borodovsky, Erin Code, Shaun M. Fillery, Jessie Hao-Ru Hsu, Sameer P. Kawatkar, Chengzhi Li, David Longmire, Youfeng Nai, Samuel C. Nash, Andrew Pike, James Robinson, Jon A. Read, Phillip B. Rawlins, Minhui Shen, Jia Tang, Peng Wang, Haley Woods & Beth Williamson. (2021) Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase. Journal of Medicinal Chemistry 64:23, pages 17146-17183.
Crossref
Crossref
Rohan Kalyan Rej, Changwei Wang, Jianfeng Lu, Mi Wang, Elyse Petrunak, Kaitlin P. Zawacki, Donna McEachern, Chao-Yie Yang, Lu Wang, Ruiting Li, Krishnapriya Chinnaswamy, Bo Wen, Duxin Sun, Jeanne A. Stuckey, Yunlong Zhou, Jianyong Chen, Guozhi Tang & Shaomeng Wang. (2021) Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression. Journal of Medicinal Chemistry 64:19, pages 14540-14556.
Crossref
Crossref
Ignacio Campillo-Marcos, Eva Monte-Serrano, Elena Navarro-Carrasco, Raúl García-González & Pedro A. Lazo. (2021) Lysine Methyltransferase Inhibitors Impair H4K20me2 and 53BP1 Foci in Response to DNA Damage in Sarcomas, a Synthetic Lethality Strategy. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Stefano Tomassi, Annalisa Romanelli, Clemens Zwergel, Sergio Valente & Antonello Mai. (2021) Polycomb Repressive Complex 2 Modulation through the Development of EZH2–EED Interaction Inhibitors and EED Binders. Journal of Medicinal Chemistry 64:16, pages 11774-11797.
Crossref
Crossref
Christine R. Keenan. (2021) Heterochromatin and Polycomb as regulators of haematopoiesis. Biochemical Society Transactions 49:2, pages 805-814.
Crossref
Crossref
Javier C. Angulo, Claudia Manini, Jose I. López, Angel Pueyo, Begoña Colás & Santiago Ropero. (2021) The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments. Cancers 13:9, pages 2071.
Crossref
Crossref